SPIN1 Antibody

What is SPIN1 and why is it significant in cancer research?

SPIN1 is a histone code reader protein that recognizes specific histone modifications and facilitates transcriptional regulation. Its significance in cancer research stems from its overexpression in multiple cancer types and its roles in promoting tumor growth and chemoresistance. Studies have demonstrated that SPIN1 is overexpressed in liposarcoma compared to normal adipose tissue or lipoma, with levels correlating with tumor aggressiveness . SPIN1 enhances proliferation and restricts apoptosis in tumor cells by activating the RET signaling pathway through direct regulation of GDNF expression . Recent research has further revealed that SPIN1 facilitates chemoresistance and homologous recombination (HR) repair by enhancing Tip60 binding to H3K9me3 . The elevated expression of SPIN1 across various cancer types compared to normal tissues suggests its potential role as a tumor promoter .

What types of SPIN1 antibodies are available for research applications?

Several types of SPIN1 antibodies have been developed for experimental use, each optimized for specific applications:

The choice of antibody depends on the experimental technique and research question. For instance, research protocols have demonstrated that anti-SPIN1(1) performs optimally in Western blot and ChIP applications, while anti-SPIN1(2) is superior for immunohistochemistry and immunofluorescence .

How can SPIN1 antibodies be validated for experimental use?

Proper validation of SPIN1 antibodies is essential for generating reliable and reproducible results. A comprehensive validation approach includes:

• Specificity Testing:

  • Western blot analysis confirming detection of a band at the expected molecular weight (~30 kDa)

  • Comparison of signals between tissues with known differential SPIN1 expression (e.g., normal adipose tissue versus liposarcoma)

  • RNA interference experiments showing signal reduction upon SPIN1 depletion

  • Use of recombinant SPIN1 as a positive control

• Application-Specific Validation:

  • For immunohistochemistry: Testing antibody performance across different tissue types with appropriate controls

  • For ChIP: Verification of enrichment at known SPIN1 binding sites

  • For co-immunoprecipitation: Confirmation of known SPIN1 interaction partners

• Cross-Validation Between Techniques:

  • Correlating protein levels detected by Western blot with immunohistochemistry findings

  • Comparing ChIP-seq binding profiles with transcriptional effects measured by RNA-seq

• Mutant Controls:

  • Using SPIN1 F141A mutants (deficient in histone binding) as functional controls

Research has shown that different SPIN1 antibodies exhibit variable performance across applications, highlighting the importance of validation for each specific experimental context.

How do SPIN1 antibodies perform in chromatin immunoprecipitation (ChIP) assays?

Optimizing SPIN1 antibodies for ChIP applications requires consideration of several technical parameters:

Antibody Selection and Protocol Optimization:

• Anti-SPIN1(1) antibody targeting amino acids 183-229 has shown superior performance in ChIP applications

• Recommend using 2-5 μg antibody per ChIP reaction with overnight incubation at 4°C

• Pre-clearing chromatin with protein A/G beads reduces background signal

Chromatin Preparation Considerations:

• Optimal crosslinking: 1% formaldehyde for 10 minutes at room temperature

• Target chromatin fragment size: 200-500 bp (optimization required for each cell type)

• Excessive sonication can destroy epitopes recognized by SPIN1 antibodies

Essential Controls:

• Input chromatin (non-immunoprecipitated)

• IgG negative control

• Positive control loci (known SPIN1 targets such as GDNF promoter)

• SPIN1-depleted cells as biological negative controls

Sequential ChIP Applications:

• For studying co-occupancy of SPIN1 with histone marks (H3K4me3, H3K9me3)

• For investigating SPIN1 interaction with transcription factors like MAZ

Research has established that SPIN1 predominantly associates with H3K4me3-marked promoter regions through its tudor-like domain 2, with binding enhanced by H3R8me2a . Recent studies have also revealed SPIN1's interaction with H3K9me3, which facilitates Tip60 recruitment and subsequent ATM activation in DNA repair contexts .

What role does SPIN1 play in DNA damage repair and chemoresistance?

Recent research has uncovered SPIN1's significant role in DNA damage repair and chemoresistance, providing important considerations for antibody-based studies:

SPIN1's Functions in DNA Repair:

• Specifically promotes homologous recombination (HR) repair pathway

• Knockdown of SPIN1 reduces HR efficiency without affecting non-homologous end joining (NHEJ)

• SPIN1 depletion decreases RAD51 and BRCA1 foci formation following irradiation while not affecting 53BP1 foci

• Facilitates ATM activation through interaction with H3K9me3 and Tip60

Chemoresistance Mechanisms:

• SPIN1 overexpression increases resistance to DNA-damaging agents including Cisplatin and Olaparib

• SPIN1 depletion enhances sensitivity to chemotherapy in both cell culture and xenograft models

• Mechanism involves promoting DNA repair efficiency and activating anti-apoptotic pathways

Experimental Approaches:

Xenograft studies using SPIN1-depleted liposarcoma cells have demonstrated significantly reduced tumor growth compared to controls, correlating with decreased GDNF expression and RET phosphorylation . Similar results were observed in chemosensitivity studies, where SPIN1 knockdown significantly enhanced tumor sensitivity to Cisplatin and Olaparib .

How can researchers troubleshoot inconsistent results with SPIN1 antibodies?

Resolving inconsistencies when using SPIN1 antibodies across different experimental platforms requires systematic troubleshooting:

Antibody-Specific Considerations:

• Validate each lot before use through Western blot and positive/negative controls

• Determine if the antibody recognizes denatured or native protein forms

• Consider using multiple antibodies targeting different epitopes for confirmation

Platform-Specific Optimization:

Sample Preparation Factors:

• Fixation methods significantly affect epitope accessibility (formalin-fixed vs. frozen)

• Protein extraction protocols influence antibody recognition

• Post-translational modifications may alter antibody binding efficiency

Cross-Validation Strategies:

• Correlate results between complementary techniques

• Implement biological validation through knockdown/knockout studies

• Verify with alternative detection methods (e.g., tagged SPIN1 constructs)

Research has demonstrated that anti-SPIN1(1) performs optimally in Western blot and ChIP applications, while anti-SPIN1(2) is superior for immunohistochemistry and immunofluorescence techniques . Understanding these application-specific preferences is crucial for experimental success.

What are the optimal protocols for quantifying SPIN1 in tumor samples?

Accurate quantification of SPIN1 in tumor samples requires optimized protocols tailored to specific research questions:

Immunohistochemistry Quantification Protocol:

• Tissue fixation: 10% neutral buffered formalin, 24 hours

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0), 20 minutes

• Blocking: 5% normal serum, 1 hour at room temperature

• Primary antibody: Anti-SPIN1(2) at 1:200 dilution, overnight at 4°C

• Detection system: HRP-conjugated secondary antibody and DAB substrate

• Scoring: Immune reactive score (IRS) combining staining intensity (0-3) and percentage of positive cells (0-4)

Quantification Methods:

• IRS system: Score = Intensity (0-3) × Percentage (0-4), yielding values from 0-12

• Digital image analysis using specialized software for more objective quantification

• Comparison with internal controls (normal tissue, other tumor grades) for standardization

Expression Patterns Across Tumor Types:

Quantitative analysis of 155 patient samples revealed that SPIN1 protein levels correlate with liposarcoma aggressiveness, with SPIN1 expression significantly increasing with the degree of malignancy . Similar patterns have been observed for GDNF, phosphorylated RET, and MAZ expression in liposarcoma samples, indicating their functional relationship in tumor progression .

How should researchers design experiments to study SPIN1's interactions with histone modifications?

Investigating SPIN1's function as a histone code reader requires specialized experimental approaches:

Biochemical Interaction Studies:

• Peptide pull-down assays using biotinylated histone peptides with specific modifications

• Surface plasmon resonance (SPR) to determine binding kinetics and affinity constants

• Isothermal titration calorimetry (ITC) for thermodynamic analysis of interactions

Structural Analysis Approaches:

• X-ray crystallography of SPIN1 bound to modified histone peptides

• NMR spectroscopy for dynamic interaction studies

• Mutational analysis targeting key residues in binding pockets (e.g., F141A mutation in tudor-like domain 2)

Cellular and Genomic Approaches:

• ChIP-seq to map genome-wide binding sites of SPIN1 in relation to histone marks

• Sequential ChIP (ChIP-reChIP) to determine co-occupancy with specific histone modifications

• CUT&RUN or CUT&Tag for higher resolution mapping of interactions

Key Histone Modifications for Investigation:

Research has established that SPIN1 binds with high affinity to H3K4me3 through its tudor-like domain 2, with binding enhanced by H3R8me2a . The F141A mutation in tudor-like domain 2 strongly impairs SPIN1 binding to H3K4me3, resulting in functional defects in proliferation and survival regulation . More recent findings indicate that SPIN1 also interacts with H3K9me3, facilitating the recruitment of Tip60 and subsequent activation of ATM in DNA damage repair contexts .

What controls are essential for studying SPIN1's role in tumor xenograft models?

Xenograft studies investigating SPIN1's functions require rigorous controls to ensure valid and reproducible results:

Cell Line Preparation Controls:

• Verification of SPIN1 knockdown/overexpression efficiency before injection

• Quantitative RT-PCR and Western blot confirmation of SPIN1 levels

• Use of inducible expression systems for temporal control

• GFP co-expression for tracking engrafted cells

Animal Model Controls:

• Age and sex-matched animals (typically BALB/c nude mice for xenograft studies)

• Randomization to treatment groups to minimize bias

• Appropriate sample sizes determined by power analysis

• Vehicle controls for drug treatment studies

Treatment Protocol Controls:

• Standardized tumor measurement techniques

• Blinded assessment of tumor parameters

• Consistent drug delivery methods and schedules

• Regular monitoring of animal health and weight

Analysis Controls and Validation:

Published xenograft studies with SPIN1-depleted liposarcoma cells have demonstrated significantly reduced tumor weight compared to controls . Analysis of these tumors showed decreased GDNF expression and RET phosphorylation, consistent with in vitro findings . Ki67 staining revealed reduced proliferation, while TUNEL assays confirmed increased apoptosis in SPIN1-depleted tumors . Similar patterns were observed in chemosensitivity studies, where SPIN1 knockdown significantly enhanced tumor sensitivity to Cisplatin and Olaparib .

How can SPIN1 antibodies be used to study its role across multiple cancer types?

SPIN1's elevated expression across various cancer types necessitates comparative analytical approaches:

Cross-Cancer Analysis Methods:

• Tissue microarrays encompassing multiple cancer types

• Standardized IHC protocols for consistent cross-type comparison

• Digital pathology platforms for objective quantification

• Correlation with cancer-specific molecular subtypes

Multi-Parameter Analysis Approaches:

• Co-expression analysis with known cancer drivers

• Integration with genomic alterations (mutations, copy number)

• Correlation with clinical parameters and outcomes

• Pathway activation assessment across cancer types

Cancer Type-Specific Considerations:

Gene Expression Profiling Interactive Analysis (GEPIA) has demonstrated significantly elevated expression levels of SPIN1 across various cancer types compared to normal tissues . These observations, combined with functional studies showing SPIN1's roles in proliferation, DNA repair, and therapy resistance, suggest that comprehensive multi-cancer analysis using validated SPIN1 antibodies could reveal both common and tissue-specific mechanisms of SPIN1 function in cancer biology.

What are the most effective approaches to studying SPIN1's function in therapy response?

SPIN1's emerging role in chemoresistance and radioresistance highlights the importance of studying its function in therapy response:

In Vitro Experimental Designs:

• Paired sensitive/resistant cell line models

• Dose-response curves following SPIN1 manipulation

• Time-course analyses of SPIN1 expression/function during resistance development

• Combination with pathway inhibitors targeting SPIN1-dependent mechanisms

In Vivo Resistance Models:

• Xenograft models with modulated SPIN1 expression

• Sequential treatment protocols mimicking clinical scenarios

• Patient-derived xenografts with known response characteristics

• Imaging-based longitudinal monitoring of tumor responses

Mechanistic Investigation Approaches:

• DNA damage repair capacity assessment (comet assay, γH2AX clearance)

• Cell survival pathway analysis (Western blot, transcriptomics)

• Chromatin dynamics studies before and after treatment

• Correlation between SPIN1 binding profiles and therapy-responsive genes

Clinical Translation Methods:

• Pre- and post-treatment tumor biopsies analysis

• Patient stratification based on SPIN1 expression/activity

• Combined analysis with established resistance biomarkers

• Development of SPIN1 inhibition strategies

Studies have demonstrated that knockdown of SPIN1 increases cancer cell sensitivity to DNA-damaging agents including Cisplatin and Olaparib, while reintroducing SPIN1 restores resistance . Xenograft models confirm these findings, showing significant reductions in tumor growth rate, weight, and size in SPIN1-depleted tumors treated with chemotherapy . These results suggest that targeting SPIN1 could enhance the effectiveness of DNA-damaging therapies in cancer treatment.